bpc-157 multiple sclerosis trial as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Size:1000 mcg/ml - 30 ml x 1 BPC-157 – JabLab Vitamin B12 Injection

bpc-157 multiple sclerosis trial as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Size:1000 mcg/ml - 30 ml x 1 BPC-157 – JabLab Vitamin B12 Injection

BPC-157 – JabLab

This risk is not theoretical

Vitamin B12 Injection

Size:1000 mcg/ml - 30 ml x 1

Ahn and Brown, 2005 Ilniczky etal, 2003: Beltramello etal, 1998: Rosener and DIchgans, 1996), neurotoxicity (Johnsonn etal, 2018), neuronopathy (Morris etal, 2015), polyneuropathy (Alarcia etal, 1999), psychosis (Sethi etal, 2006), dementia (El Otmani etal, 2007), ataxia (Miller etal, 2004), megaloblastic anemia (Barbosa etal, 2000), neurological impairment (McNeeely etal, 2000), neurologic decompensation (Felmet etal, 2000), neurologic degeneration (Flippo and Holder, 1993), spastic paraparesis (Lee etal, 1999)